We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: European Diabetes Market
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Global Healthcare > European Diabetes Market
BusinessGlobal Healthcare

European Diabetes Market

PatrickDriscoll
PatrickDriscoll
Share
2 Min Read
SHARE

Europe ranks second behind the United States in terms of the largest market for diabetes management therapies and products. One reason for the rise of diabetes in Europe is attributed to its aging population, which lends to a higher prevalence of abnormal glucose tolerance in the adult population. In 2010, roughly 33% of the European population as a whole was older than 50 years, a percentage that is expected to surpass 40% by 2030.

Europe ranks second behind the United States in terms of the largest market for diabetes management therapies and products. One reason for the rise of diabetes in Europe is attributed to its aging population, which lends to a higher prevalence of abnormal glucose tolerance in the adult population. In 2010, roughly 33% of the European population as a whole was older than 50 years, a percentage that is expected to surpass 40% by 2030.

Like most global markets, diabetes in Europe is dominated by sales of insulin, test strips and anti-diabetic drugs.  Significant growth is expected in novel technologies like continuous blood glucose monitors and integrated pumps/monitors (eventually, “artificial pancreas” products), but the existing market is still very dominated by well established diabetes products.

More Read

Drug Risks Outweigh Benefits for Some Type 2 Diabetes Patients
Diabetes 11.11.11 Collage
From Yellow Pages to Google My Hospital
8 Powerful Innovations In ICU Design
5 Huge Ways Healthcare is Changing in 2024

Source: MedMarket Diligence, LLC; Report #D510.

TAGGED:diabetes
Share This Article
Facebook Copy Link Print
Share
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Before Sterilization Begins: Why Bioburden Testing Matters -- AI-generated illustration
Before Sterilization Begins: Why Bioburden Testing Matters
Health Infographics
September 11, 2026
Hidden Cybersecurity Roadblocks That Can Complicate FDA Submissions -- AI-generated illustration
Hidden Cybersecurity Roadblocks That Can Complicate FDA Submissions
Infographics Policy & Law Technology
September 11, 2026
Smaller, Lighter, Smarter: How Inflation Is Changing Wellness Packaging -- AI-generated illustration
Smaller, Lighter, Smarter: How Inflation Is Changing Wellness Packaging
Infographics Wellness
September 11, 2026
How Roof Deterioration Affects Indoor Air Quality and the Health of Building Occupants -- AI-generated illustration
How Roof Deterioration Affects Indoor Air Quality and the Health of Building Occupants
Health
September 10, 2026

You Might also Like

Benefits of Long-Form Content in Healthcare Marketing

May 27, 2014

Pioneering Healthcare in Brazil

January 18, 2014

Hospital Chargemasters and Open Data from CMS — The Conversation Continues

May 19, 2013

Five Accelerants to the Adoption of Connected Health

February 2, 2015
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?